SML3893
LCL521 dihydrochlroide
≥95% (HPLC)
别名:
(1R,2R)-2-N-(Tetradecanoylamino)-1-(40-nitrophenyl)-propyl-1,3-O,O-di-(N,N-dimethylamino) acetate dihydrochloride, 1,3-DMG-B13, 1,3-O,O-DMG-B13•2HCl, 1,3-di-DMG-B13, B13: (1R,2R)-2-(tetradecanoylamino)-1-(4′-nitrophenyl)-1,3-propandiol), LCL 521, LCL-521
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C31H52N4O7·2HCl
CAS号:
分子量:
665.69
MDL號碼:
分類程式碼代碼:
51111800
分類程式碼代碼:
12352200
推荐产品
品質等級
化驗
≥95% (HPLC)
形狀
powder
儲存條件
desiccated
顏色
white to beige
溶解度
DMSO: 2 mg/mL, clear
儲存溫度
-10 to -25°C
SMILES 字串
CN(C)CC(O[C@H](C1=CC=C(C=C1)[N+]([O-])=O)[C@@H](COC(CN(C)C)=O)NC(CCCCCCCCCCCCC)=O)=O.[2HCl]
生化／生理作用
N,N-dimethyl glycine (DMG) diester prodrug form of the selective acid ceramidase (ACDase) inhibitor B13 for enhanced lysosomal delivery and cellular potency.
LCL521 is the N,N-dimethyl glycine (DMG) diester prodrug form of the selective acid ceramidase (ACDase) inhibitor B13 (no inhibition against NCDase/ASAH2 or AlkCDase/ACER2). The DMG enables efficient and targeted B13 lysosomal delivery, resulting in enhanced cellular ACDase inhibitory potency (by 70% vs 12% in MCF7, respectively, post 1h treatment by 1 μM LCL521 or 10 μM B13) and effective blockage of ceramide (Cer) to sphingosine (Sph) processing (80% vs 0% Sph level drop in MCF7, respectively, post 1h treatment by 1 μM LCL521 or 10 μM B13).
LCL521 is the N,N-dimethyl glycine (DMG) diester prodrug form of the selective acid ceramidase (ACDase) inhibitor B13 (no inhibition against NCDase/ASAH2 or AlkCDase/ACER2). The DMG enables efficient and targeted B13 lysosomal delivery, resulting in enhanced cellular ACDase inhibitory potency (by 70% vs 12% in MCF7, respectively, post 1h treatment by 1 μM LCL521 or 10 μM B13) and effective blockage of ceramide (Cer) to sphingosine (Sph) processing (80% vs 0% Sph level drop in MCF7, respectively, post 1h treatment by 1 μM LCL521 or 10 μM B13).
注意
Hygroscopic
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Rachael E Clifford et al.
Cells, 9(12) (2020-12-19)
Previous work utilizing proteomic and immunohistochemical analyses has identified that high levels of acid ceramidase (AC) expression confers a poorer response to neoadjuvant treatment in locally advanced rectal cancer. We aimed to assess the radiosensitising effect of biological and pharmacological
Anticancer actions of lysosomally targeted inhibitor, LCL521, of acid ceramidase
PLoS ONE, 12(6) (2017)
Mladen Korbelik et al.
International journal of cancer, 139(6), 1372-1378 (2016-05-04)
Acid ceramidase has been identified as a promising target for cancer therapy. One of its most effective inhibitors, LCL521, was examined as adjuvant to photodynamic therapy (PDT) using mouse squamous cell carcinoma SCCVII model of head and neck cancer. Lethal
Shai White-Gilbertson et al.
Journal of lipid research, 60(7), 1225-1235 (2019-04-17)
Radiation treatment failure or relapse after initial response to chemotherapy presents significant clinical challenges in cancer patients. Escape from initial courses of treatment can involve reactivation of embryonic developmental stages, with the formation of polynuclear giant cancer cells (PGCCs). This
Mladen Korbelik et al.
Methods in molecular biology (Clifton, N.J.), 2451, 569-577 (2022-05-04)
Recently, it has become clear that a prerequisite requirement for most cancer therapies is controlling the negative impact of the activity of immunosuppressory cell populations. It is therefore of a considerable interest to develop treatments for containing the operation of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门